Get started
Author

Avina K. Singh

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · Tait D. Shanafelt, Xin V. Wang, et al. · New England Journal of Medicine · 751
PDF
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
2020 · Shaji K Kumar, Susanna J Jacobus, et al. · The Lancet Oncology · 260
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
2024 · Alex F. Herrera, Michael LeBlanc, et al. · New England Journal of Medicine · 254
PDF
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
2022 · Tait D. Shanafelt, Xin Victoria Wang, et al. · Blood · 242
PDF
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial
2019 · Tait D. Shanafelt, Victoria Wang, et al. · Blood · 36
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
2021 · Xin Victoria Wang, Curtis A. Hanson, et al. · Blood · 34
PDF
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
2025 · Tait D. Shanafelt, Xin Victoria Wang, et al. · Blood Advances · 7
PDF
Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912
2021 · Priyanka A Pophali, Xin Victoria Wang, et al. · Blood · 2
Works count: 8
Citation count: 1,585
H-index: 7
I10-index: 6
Year
Topic
Type